Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Human immunodeficiency virus type 1 reverse transcriptase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | mitogen activated protein kinase | 0.0225 | 1 | 1 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0225 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0225 | 1 | 1 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0225 | 1 | 1 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0225 | 1 | 1 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0225 | 1 | 1 |
Trypanosoma brucei | unspecified product | 0.0029 | 0.0114 | 0.0114 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0225 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | ribonuclease HI | 0.0027 | 0 | 0.5 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0029 | 0.0114 | 0.0114 |
Trypanosoma brucei | RNA helicase, putative | 0.01 | 0.3691 | 0.3691 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0225 | 1 | 1 |
Onchocerca volvulus | Ribonuclease H1 homolog | 0.0027 | 0 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0225 | 1 | 1 |
Trypanosoma brucei | protein kinase, putative | 0.0225 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0225 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0225 | 1 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0225 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0225 | 1 | 1 |
Treponema pallidum | ribonuclease H (rnhA) | 0.0027 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0029 | 0.0114 | 0.0114 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0225 | 1 | 1 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0225 | 1 | 1 |
Trypanosoma brucei | retrotransposon hot spot protein 4 (RHS4), interrupted | 0.0029 | 0.0114 | 0.0114 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0225 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.01 | 0.3691 | 0.3691 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0225 | 1 | 0.5 |
Trypanosoma brucei | ingi protein (ORF1) | 0.0029 | 0.0114 | 0.0114 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0225 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0225 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (functional) | = 221 uM | Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | ChEMBL. | 1732552 |
CC50 (functional) | = 221 uM | Concentration required to reduce the viability of mock-infected MT-4 cells by 50%. | ChEMBL. | 1732552 |
EC50 (functional) | = 7.9 uM | Concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. | ChEMBL. | 1732552 |
EC50 (binding) | = 7.9 uM | Inhibitory concentration against HIV-1 reverse transcriptase | ChEMBL. | 9435895 |
EC50 (binding) | = 7.9 uM | Inhibitory concentration against HIV-1 reverse transcriptase | ChEMBL. | 9435895 |
Log 1/C (functional) | = 5.1 | Tested for 50% protection of MT-4 cells from HIV infection | ChEMBL. | No reference |
Selectivity index (functional) | = 28 | Ratio of EC50/CC50 | ChEMBL. | 1732552 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.